Clinical Trials Browser

Phase 1 × Active not recruiting × dostarlimab × Clear all

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT04387084 2026-03-23

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

Phase 1 Active not recruiting

10 enrolled

Dermatologic

Skin Neoplasms

NCT02715284 2026-01-13

GARNET

Phase 1 Active not recruiting

730 enrolled 3 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT04673448 2026-01-09

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1 Active not recruiting

18 enrolled

BreastGastrointestinalGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms

NCT03843359 2026-01-08

A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors

Phase 1 Active not recruiting

97 enrolled 45 charts

Bites and Stings, Neoplasms

NCT03955978 2026-01-06

TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer

Phase 1 Active not recruiting

10 enrolled

Gynecologic

Endometrial Neoplasms

NCT02817633 2025-10-28

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Phase 1 Active not recruiting

463 enrolled

DermatologicGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Colorectal Neoplasms

NCT04446351 2025-10-27

Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors

Phase 1 Active not recruiting

107 enrolled

Tumor-Agnostic

Neoplasms

Clinical Trials

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

GARNET

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors

TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors